Drug treatment in acute porphyria

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Acute hepatic porphyrias (AHPs) are rare, autosomal dominant pharmacogenetic disorders characterized by a 50% deficiency in a heme biosynthetic pathway enzyme.
• Patients experience debilitating neurovisceral attacks, including severe abdominal pain, neuropsychiatric symptoms, and potentially fatal respiratory paralysis.
• Attacks are more common in females post-puberty and can be triggered by hormonal changes, diet, alcohol, infections, and certain medications.

Purpose of the Study:

• To summarize the key aspects of acute hepatic porphyrias, focusing on diagnosis, management, and prevention.
• To highlight the importance of genetic testing for family members and the cautious approach needed for drug selection.
• To emphasize the diagnostic significance of elevated porphobilinogen in urine during acute attacks.

Main Methods:

• Review of existing literature on acute hepatic porphyrias.
• Analysis of clinical presentation, diagnostic criteria, and treatment strategies.
• Evaluation of drug safety data and recommendations for avoidance of porphyrinogenic substances.

Main Results:

• Neurovisceral attacks in AHPs can mimic abdominal emergencies, leading to potential medication-induced exacerbations.
• Urine porphobilinogen testing is pathognomonic for acute attacks.
• Genetic determination in relatives allows for proactive avoidance of precipitants in carriers.

Conclusions:

• Prompt diagnosis and management, including analgesia and heme administration, are vital for AHP patients.
• Identifying and avoiding drug and environmental triggers is essential for preventing attacks in individuals with AHPs.
• Further research is needed to clarify the relevance of animal and in vitro drug studies to human AHP conditions.